Wall Street Zen cut shares of Vivani Medical (NASDAQ:VANI – Free Report) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Vivani Medical currently has an average rating of “Hold” and an average target price of $3.75.
View Our Latest Stock Report on VANI
Vivani Medical Price Performance
VANI stock opened at $1.12 on Friday. The firm’s fifty day simple moving average is $1.21 and its 200-day simple moving average is $1.25. The company has a market capitalization of $101.47 million, a P/E ratio of -3.21 and a beta of 2.51. Vivani Medical has a 12 month low of $0.92 and a 12 month high of $1.66.
Vivani Medical (NASDAQ:VANI – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. As a group, sell-side analysts forecast that Vivani Medical will post -0.30 earnings per share for the current year.
About Vivani Medical
Vivani Medical, Inc is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence.
The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes.
Read More
- Five stocks we like better than Vivani Medical
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
